Indivior PLC
LSE:INDV

Watchlist Manager
Indivior PLC Logo
Indivior PLC
LSE:INDV
Watchlist
Price: 914.5 GBX 0.11% Market Closed
Market Cap: 1.2B GBX
Have any thoughts about
Indivior PLC?
Write Note

Relative Value

The Relative Value of one INDV stock under the Base Case scenario is 2 151.89 GBX. Compared to the current market price of 914.5 GBX, Indivior PLC is Undervalued by 58%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

INDV Relative Value
Base Case
2 151.89 GBX
Undervaluation 58%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
96
vs Industry
65
Median 3Y
2.8
Median 5Y
2.9
Industry
2.5
Forward
0
vs History
vs Industry
1
Median 3Y
10.6
Median 5Y
8.9
Industry
21.8
Forward
0.1
vs History
vs Industry
3
Median 3Y
-6.5
Median 5Y
-6.5
Industry
16.1
vs History
vs Industry
Median 3Y
-5.8
Median 5Y
-5.8
Industry
23.8
vs History
vs Industry
0
Median 3Y
11.8
Median 5Y
12.7
Industry
2.1
vs History
vs Industry
Median 3Y
-43.3
Median 5Y
-78.1
Industry
2.7
Forward
-0.1
vs History
vs Industry
Median 3Y
-52.2
Median 5Y
-93.1
Industry
5.2
vs History
vs Industry
2
Median 3Y
-166.1
Median 5Y
-293.7
Industry
13.5
Forward
-0.3
vs History
vs Industry
3
Median 3Y
-182.3
Median 5Y
-326.6
Industry
16.8
Forward
-0.4
vs History
34
vs Industry
27
Median 3Y
11.6
Median 5Y
11.6
Industry
15.2
vs History
34
vs Industry
27
Median 3Y
10.1
Median 5Y
10.1
Industry
19.3
vs History
vs Industry
Median 3Y
-40.6
Median 5Y
-91.6
Industry
1.9

Multiples Across Competitors

INDV Competitors Multiples
Indivior PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Indivior PLC
LSE:INDV
1.2B GBP 1.3 -10.9 -30.4 -36.2
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
729.3B USD 17.8 87.1 46.9 52.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
2.6T DKK 9.6 27.5 19.1 21.8
US
Johnson & Johnson
NYSE:JNJ
347.8B USD 4 23.7 11.5 14.9
US
Merck & Co Inc
NYSE:MRK
248.3B USD 3.9 20.4 10.3 12.4
CH
Roche Holding AG
SIX:ROG
197.2B CHF 3.4 17.2 9.7 11.5
UK
AstraZeneca PLC
LSE:AZN
159B GBP 4.1 31 169.2 253.5
CH
Novartis AG
SIX:NOVN
169.7B CHF 3.8 10.8 9.4 13
US
Pfizer Inc
NYSE:PFE
149.4B USD 2.5 35.1 10.5 15.8
P/S Multiple
Revenue Growth P/S to Growth
UK
Indivior PLC
LSE:INDV
Average P/S: 382 942
1.3
12%
0.1
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
4 211 733
22%
194 879.4
US
Eli Lilly and Co
NYSE:LLY
17.8
109%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
578.3
29%
19.9
DK
Novo Nordisk A/S
CSE:NOVO B
9.6
77%
0.1
US
Johnson & Johnson
NYSE:JNJ
4
13%
0.3
US
Merck & Co Inc
NYSE:MRK
3.9
20%
0.2
CH
Roche Holding AG
SIX:ROG
3.4
15%
0.2
UK
AstraZeneca PLC
LSE:AZN
4.1
35%
0.1
CH
Novartis AG
SIX:NOVN
3.8
17%
0.2
US
Pfizer Inc
NYSE:PFE
2.5
10%
0.3
P/E Multiple
Earnings Growth P/E to Growth
UK
Indivior PLC
LSE:INDV
Average P/E: 31.6
Negative Multiple: -10.9
13 493%
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
87.1
446%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
27.5
86%
0.3
US
Johnson & Johnson
NYSE:JNJ
23.7
-23%
N/A
US
Merck & Co Inc
NYSE:MRK
20.4
7 300%
0
CH
Roche Holding AG
SIX:ROG
17.2
54%
0.3
UK
AstraZeneca PLC
LSE:AZN
31
177%
0.2
CH
Novartis AG
SIX:NOVN
10.8
31%
0.3
US
Pfizer Inc
NYSE:PFE
35.1
719%
0
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Indivior PLC
LSE:INDV
Average EV/EBITDA: 459.2
Negative Multiple: -30.4
25%
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
46.9
195%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
151%
25.5
DK
Novo Nordisk A/S
CSE:NOVO B
19.1
84%
0.2
US
Johnson & Johnson
NYSE:JNJ
11.5
14%
0.8
US
Merck & Co Inc
NYSE:MRK
10.3
331%
0
CH
Roche Holding AG
SIX:ROG
9.7
23%
0.4
UK
AstraZeneca PLC
LSE:AZN
169.2
64%
2.6
CH
Novartis AG
SIX:NOVN
9.4
8%
1.2
US
Pfizer Inc
NYSE:PFE
10.5
31%
0.3
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Indivior PLC
LSE:INDV
Average EV/EBIT: 2 010.8
Negative Multiple: -36.2
26%
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.3
211%
0.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
26.2
DK
Novo Nordisk A/S
CSE:NOVO B
21.8
83%
0.3
US
Johnson & Johnson
NYSE:JNJ
14.9
28%
0.5
US
Merck & Co Inc
NYSE:MRK
12.4
675%
0
CH
Roche Holding AG
SIX:ROG
11.5
28%
0.4
UK
AstraZeneca PLC
LSE:AZN
253.5
131%
1.9
CH
Novartis AG
SIX:NOVN
13
58%
0.2
US
Pfizer Inc
NYSE:PFE
15.8
68%
0.2

See Also

Discover More
Back to Top